Institute of Liver, Gastroenterology, and Pancreatico-Biliary Sciences, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, 110 060, India.
Department of Gastroenterology and Hepatology, Kalinga Institute of Medical Sciences, Kushabhadra Campus, 5, KIIT Road, Bhubaneswar, 751 024, India.
Indian J Gastroenterol. 2023 Jun;42(3):332-346. doi: 10.1007/s12664-022-01324-6. Epub 2023 Jun 5.
Antiplatelet and/or anticoagulant agents (collectively known as antithrombotic agents) are used to reduce the risk of thromboembolic events in patients with conditions such as atrial fibrillation, acute coronary syndrome, recurrent stroke prevention, deep vein thrombosis, hypercoagulable states and endoprostheses. Antithrombotic-associated gastrointestinal (GI) bleeding is an increasing burden due to the growing population of advanced age with multiple comorbidities and the expanding indications for the use of antiplatelet agents and anticoagulants. GI bleeding in antithrombotic users is associated with an increase in short-term and long-term mortality. In addition, in recent decades, there has been an exponential increase in the use of diagnostic and therapeutic GI endoscopic procedures. Since endoscopic procedures hold an inherent risk of bleeding that depends on the type of endoscopy and patients' comorbidities, in patients already on antithrombotic therapies, the risk of procedure-related bleeding is further increased. Interrupting or modifying doses of these agents prior to any invasive procedures put these patients at increased risk of thromboembolic events. Although many international GI societies have published guidelines for the management of antithrombotic agents during an event of GI bleeding and during urgent and elective endoscopic procedures, no Indian guidelines exist that cater to Indian gastroenterologists and their patients. In this regard, the Indian Society of Gastroenterology (ISG), in association with the Cardiological Society of India (CSI), Indian Academy of Neurology (IAN) and Vascular Society of India (VSI), have developed a "Guidance Document" for the management of antithrombotic agents during an event of GI bleeding and during urgent and elective endoscopic procedures.
抗血小板和/或抗凝剂(统称为抗血栓形成剂)用于降低患有心房颤动、急性冠脉综合征、复发性中风预防、深静脉血栓形成、高凝状态和内置假体等疾病的患者发生血栓栓塞事件的风险。由于高龄人群不断增加,且合并多种疾病,以及抗血小板药物和抗凝剂的使用指征不断扩大,抗血栓形成相关的胃肠道(GI)出血的负担日益加重。抗血栓形成药物使用者的 GI 出血与短期和长期死亡率的增加有关。此外,近几十年来,诊断和治疗性 GI 内镜检查程序的使用呈指数级增长。由于内镜检查程序本身存在出血风险,具体取决于内镜检查的类型和患者的合并症,因此在已经接受抗血栓治疗的患者中,与程序相关的出血风险进一步增加。在任何有创性程序之前中断或调整这些药物的剂量会使这些患者发生血栓栓塞事件的风险增加。尽管许多国际胃肠病学会已经发布了关于 GI 出血和紧急及择期内镜检查期间抗血栓形成药物管理的指南,但印度并没有针对印度胃肠病学家及其患者的指南。在这方面,印度胃肠病学会(ISG)与印度心脏病学会(CSI)、印度神经病学学会(IAN)和印度血管学会(VSI)合作,制定了“指南文件”,以管理 GI 出血和紧急及择期内镜检查期间的抗血栓形成药物。